This is a minimal risk feasibility study involving the analysis of patient samples and does not involve any therapeutic intervention. The study will involve a prospective cohort of up to 60 patients diagnosed with Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma (LA-OPSCC) treated with chemoradiotherapy (CRT) at Princess Margaret Cancer Centre.
To assess the feasibility of microbiome evaluation in LA-OPSCC patients undergoing CRT using samples collected by four different methods: Saliva, Oropharyngeal swab over the tumor site (OP), Stool, and Rectal swab (optional). This study is investigating the role of oral microbiota as a biomarker in LA-OPSCC. This is a minimal risk study involving the analysis of patient samples and does not involve therapeutic intervention. This protocol does not determine eligibility to receive treatment with concurrent radiotherapy and chemotherapy. It is anticipated that patient accrual will be completed within 12 months. The study will involve a prospective cohort of up to 60 patients diagnosed with LA OPSCC treated with CRT at Princess Margaret Cancer Center.
Study Type
OBSERVATIONAL
Enrollment
26
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Feasibility of microbiome evaluation in LA-OPSCC patients undergoing CRT using samples collected by four different methods
To assess the feasibility, the endpoint will be the proportion of analyzable samples.
Time frame: 1 year
Feasibility of microbiome evaluation in LA-OPSCC patients undergoing CRT using samples collected by four different methods
To assess the feasibility, the endpoint will be the patient compliance rate with sample collection timeline/procedures.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.